Proteocyte AI

Home
Canada
Toronto, ON
Proteocyte AI

A Canadian molecular diagnostics company with a novel technology that determines the risk of a head

Better cancer diagnostics

Our novel diagnostic technology, Straticyte™, determines the risk of a head and neck lesion becoming cancerous in the near future. If the risk is high, clinicians can provide early interventions. Clinicians can follow-up effectively with moderate and low risk lesions. Accurate early diagnosis and treatment will drastically improve the clinical outcomes and quality of life for people with head and neck cancer.

11/20/2025

Thank you to everyone who joined the AAOM Educational Webinar: AI and Biomarker-Guided Diagnostics in Oral Lesions: From Risk Stratification to Clinical Pathways.

An excellent CE event with valuable insights shared by 2 experts in their respective fields; Dr. Paras Patel, Oral and Maxillofacial PathologistDirector of the Oral Maxillofacial Pathology Department at Propath, Dallas, TX and Dr. Waleed Zaid, Professor, Fellowship Director, Head and Neck Oncology and Microvascular Surgery, LSU Health New Orleans

Couldn’t make it live? You can view the recording and learn more about Proteocyte AI and the role of prognostic tools in oral cancer risk assessment here: https://vimeo.com/1134602267?share=copy

Ontario Dental Association , American Association of Oral and Maxillofacial Surgeons - AAOMS , American Academy of Oral Medicine , American Academy of Oral and Maxillofacial Pathology - AAOMP , Canadian Dental Association , Canadian Association of Oral and Maxillofacial Surgeons , ™, American Academy of Otolaryngology—Head and Neck Surgery , American Dental Association , SurgeOn Events

11/18/2025

Get to know the Proteocyte team!

Meet our Principal Scientist & Lab Manager, Jason Hwang. Jason is fluent in the field of cell differentiation/signaling and cancer metastasis, with over 10 years of research lab experience. He has overseen multiple research projects including the supervision of graduate/undergraduate students and other lab members, and is the co-inventor of Proteocyte’s first patent for the automated method for assessing oral cancer risk progression. He obtained his HBSc in Cell biology, and his MSc and PhD in Cell & Developmental Biology from The University of Western Ontario in London, Ontario.

“Advances in protein biomarker-based computational analysis are driving the adoption of digital pathology and machine learning–based diagnostics across modern healthcare. Proteocyte’s flagship product, Straticyte, utilizes high-resolution whole-slide imaging and advanced AI analysis to deliver individualized, quantitative, and reproducible assessments of oral cancer transformation risk—enhancing and complementing traditional histopathology. Having been part of Proteocyte's journey over the past decade and finally seeing this innovation take flight has been an incredibly rewarding experience."

Ontario Dental Association , American Association of Oral and Maxillofacial Surgeons - AAOMS , American Academy of Oral Medicine , American Academy of Oral and Maxillofacial Pathology - AAOMP , Canadian Dental Association , Canadian Association of Oral and Maxillofacial Surgeons , ™, American Academy of Otolaryngology—Head and Neck Surgery , American Dental Association , SurgeOn Events

11/12/2025

Why should oral healthcare providers involved in the detection and treatment of oral cancer take interest in STRATICYTE ?

Early detection and early prediction is critical in oral cancer care — but traditional histopathology has limits in predicting which lesions may progress.

STRATICYTE™ provides a personalized risk score that helps clinicians:
✔️ Identify LOW risk and AT risk cases with greater accuracy
✔️ Intervene earlier for better outcomes
✔️ Improve patient communication and compliance with follow-up

By supporting more informed decision-making, STRATICYTE™ represents an important advancement in the fight against oral cancer.

➡️ Watch the video: https://proteocyte.com/video-gallery/
✅ To order the STRATICYTE test or to learn more: https://proteocyte.com/ordering-options/

Ontario Dental Association , American Association of Oral and Maxillofacial Surgeons - AAOMS , American Academy of Oral Medicine , American Academy of Oral and Maxillofacial Pathology - AAOMP , Canadian Dental Association , Canadian Association of Oral and Maxillofacial Surgeons , ™, American Academy of Otolaryngology—Head and Neck Surgery , American Dental Association , SurgeOn Events

11/04/2025

⏳ Just 2 Days Away!

Join us Thursday, November 6 at 7 PM ET for the AAOM Educational Webinar: AI and Biomarker-Guided Diagnostics in Oral Lesions: From Risk Stratification to Clinical Pathways

Hosted by AAOM and proudly sponsored by Proteocyte AI, this session will feature Drs. Paras Patel and Waleed Zaid, who will discuss how AI and biomarker-guided tools—like STRATICYTE™—are shaping the future of oral cancer diagnostics.

🎓 Earn 1 CE credit
📅 November 6 | 7–8 PM ET
🔗 Register now: https://www.aaom.com/webinars
✅ To order the STRATICYTE test or to learn more: https://proteocyte.com/ordering-options/

Ontario Dental Association , American Association of Oral and Maxillofacial Surgeons - AAOMS , American Academy of Oral Medicine , American Academy of Oral and Maxillofacial Pathology - AAOMP , Canadian Dental Association , Canadian Association of Oral and Maxillofacial Surgeons , ™, American Academy of Otolaryngology—Head and Neck Surgery , American Dental Association , SurgeOn Events

11/01/2025

✨November is Mouth Cancer Action Month

💡 Did you know?*
• Worldwide mouth cancer affects 650,000 people per year
• Incidence of mouth cancer have risen by 49% over the past 10 years
• 78% of cases occur in people over the age of 55
• 53% of all mouth cancers are diagnosed at stage IV

Proteocyte AI is transforming cancer risk prediction with advanced biomarker analysis and digital pathology. Our flagship product, STRATICYTE™, empowers healthcare professionals to identify oral cancer risk early, supporting personalized treatment plans and improved patient outcomes.
STRATICYTE™ represents an important advancement in the fight against oral cancer by supporting more informed decision-making.

✅ To order the STRATICYTE test or to learn more: https://proteocyte.com/ordering-options/
Mouth Cancer Action Month is held in November every year and is supported by the Cancer Foundation and the Health Foundation.

References: *https://www.mouthcancerfoundation.org/mouth-cancer-facts-and-figures/

Dental Association , Association of Oral and Maxillofacial Surgeons-AAOMS, , , , , , ™, Academy of Otolaryngology—Head and Neck Surgery , American Dental Association

10/30/2025

Proteocyte Team Member Spotlight – Dr. Barrie Renick

Get to know the Proteocyte team!

Meet Proteocyte’s Chief Medical Officer for Canada, Dr. Barrie Renick. Dr. Renick has a broad-based oral surgery practice but an interest in dental cysts and tumours but particularly mucosal disease. He has been in private practice in Newmarket and a Staff surgeon at Southlake Hospital for over 30 years. He has dual specialty training in both oral surgery and oral pathology. His training included experience at Toronto General and Toronto Western Hospitals, The Wellesley Hospital, Sick Kids, Sunnybrook Hospital, Odette Cancer Clinic, Princess Margaret Hospital, and the both the Sunnybrook and UHN Interdisciplinary Mouth Clinics.

“For the first 20+ years of my practice I struggled with the management of oral precancer or oral potential malignant disease (OPMD) patients. Some developed cancer. Some did not. It was a real guessing game, making patient management extremely difficult. The Straticyte test ended the speculation. Using the Straticyte test I could finally, correctly identify, the high risk OPMD patient, and confidently develop an appropriate treatment plan. The guessing was over. I was so impressed with the performance of the Straticyte test, I joined the Proteocyte team to educate my colleagues on how Straticyte could revolutionize care of their patients.”

Ontario Dental Association , American Association of Oral and Maxillofacial Surgeons - AAOMS , American Academy of Oral Medicine , American Academy of Oral and Maxillofacial Pathology - AAOMP , Canadian Dental Association , Canadian Association of Oral and Maxillofacial Surgeons , ™, American Academy of Otolaryngology—Head and Neck Surgery , American Dental Association , SurgeOn Events

10/28/2025

🗓️ Save the Date!

Proteocyte AI is proud to sponsor the upcoming AAOM Educational Webinar (1 CE credit offered): AI and Biomarker-Guided Diagnostics in Oral Lesions: From Risk Stratification to Clinical Pathways

📅 November 6, 2025 | 7:00–8:00 PM ET

Join Drs. Paras Patel and Waleed Zaid as they explore how AI and biomarker-driven tools like STRATICYTE™ are transforming the prediction and management of oral potentially malignant disorders (OPMDs).

🔗 Learn more and register through AAOM: https://www.aaom.com/webinars

Ontario Dental Association , American Association of Oral and Maxillofacial Surgeons - AAOMS , American Academy of Oral Medicine , American Academy of Oral and Maxillofacial Pathology - AAOMP , Canadian Dental Association , Canadian Association of Oral and Maxillofacial Surgeons , ™, American Academy of Otolaryngology—Head and Neck Surgery , American Dental Association , SurgeOn Events

10/23/2025

Thank you to everyone who joined our surgeON education webinar on Risk Stratification in Oral Precancerous Lesions: Patient Management using AI-Driven Molecular Prognostics.

Our expert panel explored how innovations like STRATICYTE™ are a valuable service to patients providing a next level of pathologic assessment, providing more information about a patient’s premalignant lesion and helping clinicians:

✔️ Go beyond what’s visible under the microscope
✔️ Identify which lesions carry elevated cancer risk
✔️ Support effective patient management and follow-up compliance

Couldn’t make it live? You can view the recording and learn more about Proteocyte AI and the role of prognostic tools in oral cancer risk assessment here: 🔗 https://www.surgeon-events.org/event-details/risk-stratification-in-oral-precancerous-lesions-patient-management-using-ai-driven-molecular-prognostics

Ontario Dental Association , American Association of Oral and Maxillofacial Surgeons - AAOMS , American Academy of Oral Medicine , American Academy of Oral and Maxillofacial Pathology - AAOMP , Canadian Dental Association , Canadian Association of Oral and Maxillofacial Surgeons , ™, American Academy of Otolaryngology—Head and Neck Surgery , American Dental Association , SurgeOn Events

10/21/2025

🌟 What are the potential benefits of integrating STRATICYTE™ into practice, for both patient outcomes and clinical workflow?

For patients:
✔️ Earlier, more precise risk assessment
✔️ Informed treatment planning
✔️ Improved long-term outcomes

For clinicians:
✔️ A complementary tool to histopathology
✔️ Clearer insights for patient communication
✔️ Streamlined workflow and decision-making

🎥 In this video, Dr. Paras Patel shares how STRATICYTE is helping reshape OPMD management in clinical practice.

➡️ Watch the video: https://proteocyte.com/video-gallery/

Ontario Dental Association , American Association of Oral and Maxillofacial Surgeons - AAOMS , American Academy of Oral Medicine , American Academy of Oral and Maxillofacial Pathology - AAOMP , Canadian Dental Association , Canadian Association of Oral and Maxillofacial Surgeons , ™, American Academy of Otolaryngology—Head and Neck Surgery , American Dental Association , SurgeOn Events

10/07/2025

How does STRATICYTE™ compare to the current standard of care for evaluating OPMDs? Does it offer a clinical advantage?

STRATICYTE is a predictive diagnostic tool that identifies which lesions are more likely to progress to cancer—offering clinicians risk assessment beyond what’s visible under the microscope.

🎥 In this short video, Dr. Paras Patel, DDS, FRCD(C), explains how STRATICYTE works alongside traditional diagnostics to support earlier, more confident decision-making.

➡️ Watch the video: https://proteocyte.com/video-gallery/

Ontario Dental Association , American Association of Oral and Maxillofacial Surgeons - AAOMS , American Academy of Oral Medicine , American Academy of Oral and Maxillofacial Pathology - AAOMP , Canadian Dental Association , Canadian Association of Oral and Maxillofacial Surgeons , ™, American Academy of Otolaryngology—Head and Neck Surgery , American Dental Association , SurgeOn Events

10/02/2025

🔬 Clinical Evidence Behind STRATICYTE™
Accurately predicting which oral precancerous lesions will progress to cancer has long been a challenge for clinicians. Traditional dysplasia grading can be subjective and inconsistent—leaving both patients and providers uncertain.

That’s why Proteocyte developed STRATICYTE™, an AI-driven prognostic test delivering a personalized 5-year risk score to guide patient management with confidence.

📄 A recent abstract published in the Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology (OOOO Journal) concluded that Straticyte demonstrated a reduction of downstream management costs, $75,000/patient and $4.37billion annually in the US, compared to oral epithelial dysplasia grading, owing to improved early detection of localized oral cancers, enabling earlier intervention.

👉 Read the full article: https://www.oooojournal.net/article/S2212-4403(25)00996-4/fulltext #:~:text=Results.%20The%20distribution%20of%20patients%20identified%20and,and%20$4.37%20billion%20annually%20in%20the%20US

👉 Explore more peer-reviewed publications supporting STRATICYTE™: https://proteocyte.com/publications/

Ontario Dental Association , American Association of Oral and Maxillofacial Surgeons - AAOMS , American Academy of Oral Medicine, American Academy of Oral and Maxillofacial Pathology - AAOMP, , , ™, American Academy of Otolaryngology—Head and Neck Surgery , American Dental Association, -events

09/30/2025

Register for this FREE webinar

🗓 Risk Stratification in Oral Precancerous Lesions: Patient Management using AI-Driven Molecular Prognostics
🕒02 Oct 2025, 16:00 – 17:30 GMT-7
Check website event info for timezones

🔗 Event details:
https://www.surgeon-events.org/event-details/risk-stratification-in-oral-precancerous-lesions-patient-management-using-ai-driven-molecular-prognostics

🤝 In collaboration with Proteocyte AI
Discover Straticyte™ — the groundbreaking prognostic test that revolutionizes oral cancer risk stratification with advanced AI-driven pathology.

🔗 Learn more about Straticyte™:
https://proteocyte.com/

✨ Don’t miss this amazing opportunity to learn and connect with top surgeons in the field, while exploring cutting-edge innovations like Proteocyte AI’s Straticyte™ solution. Whether you’re a seasoned professional or just starting your journey, this event is tailored to provide valuable insights, networking, and tools to transform clinical practice.
🚀 Secure your spot now — see you there!

Ontario Dental Association, , -academy-of-oral-medicine, -academy-of-oral-pathology, Canadian Dental Association, Canadian Association of Oral and Maxillofacial Surgeons, ™, American Academy of Otolaryngology—Head and Neck Surgery, American Dental Association, -events

Address

Toronto, ON
M5G1L7

Website

https://proteocyte.com/

Alerts

Be the first to know and let us send you an email when Proteocyte AI posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Proteocyte AI:

Shortcuts

Want your practice to be the top-listed Clinic in Toronto?